Telomerase Inhibitors
1 drugsAbout Telomerase
Telomerase is a ribonucleoprotein enzyme that maintains telomeres, the protective caps on chromosomes that shorten with cell division. It is typically inactive in normal cells, leading to senescence, but is reactivated in cancer cells, promoting immortality and tumor growth.
Telomerase is a compelling oncology target because its activity is critical for cancer cell survival. While there is currently no genetic evidence directly linking telomerase mutations to specific diseases, its role in cancer makes it therapeutically relevant.
Telomerase is targeted by one FDA-approved drug, RYTELO, a small molecule developed by GERON for oncology indications. RYTELO was first approved in 2024, demonstrating the clinical viability of telomerase inhibition.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Childhood Acute Myeloid Leukemia with only 1 trials.
Top Drugs
GERON is the only company with an approved telomerase-targeting drug.
The market is highly concentrated, suggesting high barriers to entry or limited investment in this target class.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Telomerase, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or gene therapies.
Clinical Trials 33 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 9 | 2 | 4 | 82% |
| Phase 2 | 12 | 5 | 3 | 4 | 63% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2024 - 2024)
RYTELO was the first and most recent drug approved in 2024.
The recent approval suggests renewed interest in telomerase inhibition, but further approvals are needed to confirm this trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 14 clinical trials targeting Telomerase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities